<DOC>
	<DOCNO>NCT00846807</DOCNO>
	<brief_summary>An observational cohort study safety efficacy 220 mg dose Pradaxa generate additional data predefined sub population patient increase risk bleeding VTE</brief_summary>
	<brief_title>Pradaxa ( Dabigatran Etexilate 220 mg/q.d . General Population After Hip Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Patients 18 year age undergo elective total hip knee replacement surgery consent write participation observational study Exclusion criterion : All patient treat Pradaxa 220 mg accord European Summary Product Characteristics ( SPC ) : age &gt; 75 year , renal impairment ( creatinine clearance &lt; 50 ml/min ) , patient concomitant therapy amiodarone , elevate liver enzymes &gt; 2 upper limit normal ( ULN ) and/or hepatic impairment liver disease expect impact survival , anaesthesia post operative indwell epidural catheter , hypersensitivity dabigatran etexilate excipients , active clinically significant bleeding , organic lesion risk bleeding , spontaneous pharmacological impairment haemostasis except included patient group , concomitant treatment quinidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>